Matthias Zehner
Overview
Explore the profile of Matthias Zehner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
803
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schultz E, Ponsness L, Lanchy J, Zehner M, Klein F, Ryckman B
bioRxiv
. 2025 Jan;
PMID: 39829861
Herpesviruses require membrane fusion for entry and spread, a process facilitated by the fusion glycoprotein B (gB) and the regulatory factor gH/gL. The human cytomegalovirus (HCMV) gH/gL can be modified...
2.
Korenkov M, Zehner M, Cohen-Dvashi H, Borenstein-Katz A, Kottege L, Janicki H, et al.
Immunity
. 2023 Nov;
56(12):2803-2815.e6.
PMID: 38035879
Somatic hypermutation (SHM) drives affinity maturation and continues over months in SARS-CoV-2-neutralizing antibodies (nAbs). However, several potent SARS-CoV-2 antibodies carry no or only a few mutations, leaving the question of...
3.
Zehner M, Alt M, Ashurov A, Goldsmith J, Spies R, Weiler N, et al.
Immunity
. 2023 Nov;
56(11):2602-2620.e10.
PMID: 37967532
Human cytomegalovirus (HCMV) can cause severe diseases in fetuses, newborns, and immunocompromised individuals. Currently, no vaccines are approved, and treatment options are limited. Here, we analyzed the human B cell...
4.
Gruell H, Vanshylla K, Korenkov M, Tober-Lau P, Zehner M, Munn F, et al.
Cell Host Microbe
. 2022 Aug;
30(9):1231-1241.e6.
PMID: 35921836
SARS-CoV-2 neutralizing antibodies play a critical role in COVID-19 prevention and treatment but are challenged by viral evolution and the emergence of novel escape variants. Importantly, the recently identified Omicron...
5.
Ercanoglu M, Gieselmann L, Dahling S, Poopalasingam N, Detmer S, Koch M, et al.
iScience
. 2022 Feb;
25(3):103951.
PMID: 35224466
Preexisting immunity against SARS-CoV-2 may have critical implications for our understanding of COVID-19 susceptibility and severity. The presence and clinical relevance of a preexisting B cell immunity remain to be...
6.
Halwe S, Kupke A, Vanshylla K, Liberta F, Gruell H, Zehner M, et al.
Viruses
. 2021 Aug;
13(8).
PMID: 34452363
Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important...
7.
Theobald S, Simonis A, Georgomanolis T, Kreer C, Zehner M, Eisfeld H, et al.
EMBO Mol Med
. 2021 Jun;
13(8):e14150.
PMID: 34133077
Innate immunity triggers responsible for viral control or hyperinflammation in COVID-19 are largely unknown. Here we show that the SARS-CoV-2 spike protein (S-protein) primes inflammasome formation and release of mature...
8.
Gieselmann L, Kreer C, Ercanoglu M, Lehnen N, Zehner M, Schommers P, et al.
Nat Protoc
. 2021 May;
16(7):3639-3671.
PMID: 34035500
As exemplified by the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there is a strong demand for rapid high-throughput isolation pipelines to identify potent neutralizing antibodies for prevention...
9.
Vanshylla K, Di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, et al.
Cell Host Microbe
. 2021 May;
29(6):917-929.e4.
PMID: 33984285
Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild...
10.
Kreer C, Zehner M, Weber T, Ercanoglu M, Gieselmann L, Rohde C, et al.
Cell
. 2020 Sep;
182(6):1663-1673.
PMID: 32946786
No abstract available.